Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARD-101 in Prader-Willi Syndrome
NCT05153434Phase 2Completed
- Sponsor
- Aardvark Therapeutics, Inc.
- Start
- May 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ARD-101 in Prader-Willi syndrome (PWS) (2 arms), sponsored by Aardvark Therapeutics, Inc. Primary endpoint: Incidence of Treatment Emergent Adverse Events at 70 days. Started May 2022; status: completed.
02
Drugs
ARD-101
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT05153434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05153434.